Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous o...

Por Matulonis, U. A., Wulf, G. M., Barry, W. T., Birrer, M., Westin, S. N., Farooq, S., Bell-McGuinn, K. M., Obermayer, E., Whalen, C., Spagnoletti, T., Luo, W., Liu, H., Hok, R. C., Aghajanian, C., Solit, D. B., Mills, G. B., Taylor, B. S., Won, H., Berger, M. F., Palakurthi, S., Liu, J., Cantley, L. C., Winer, E.
Publicado no Ann Oncol (2017)